Payment overview · 2025
General Payments
$357.16
4 reported records · 3 companies
Healthcare provider profile · identity verified
Rakesh Mittal, MD, PHD
Allopathic & Osteopathic Physicians|Hospitalist · ST PETERSBURG, FL · NPI 1023046562
Verified facts
What the public records show
CMS Open Payments records show Rakesh Mittal, MD, PHD received $357.16 in general payments during 2025 across 4 reported records.
Abbott Laboratories accounted for 60.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $214.78 | 60.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $125.00 | 35.0% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $17.38 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $339.78 | 3 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $214.78 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 300 | 81 |
| Eliquis | Apixaban | 249 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 240 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 219 | 64 |
| Furosemide | Furosemide | 216 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 213 | 52 |
| Lisinopril | Lisinopril | 179 | 53 |
| Gabapentin | Gabapentin | 160 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 143 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 141 | 40 |
| Potassium Chloride | Potassium Chloride | 139 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 36 |
| Losartan Potassium | Losartan Potassium | 131 | 43 |
| Carvedilol | Carvedilol | 123 | 32 |
| Tramadol Hcl | Tramadol Hcl | 122 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 119 | 32 |
| Famotidine | Famotidine | 118 | 32 |
| Allopurinol | Allopurinol | 99 | 24 |
| Jardiance | Empagliflozin | 95 | 15 |
| Linzess | Linaclotide | 88 | 26 |
| Pregabalin | Pregabalin | 87 | 30 |
| Alprazolam | Alprazolam | 84 | 14 |
| Spironolactone | Spironolactone | 80 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 22 |
| Omeprazole | Omeprazole | 76 | 27 |
| Methenamine Hippurate | Methenamine Hippurate | 75 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 21 |
| Trazodone Hcl | Trazodone Hcl | 72 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 12 |
| Montelukast Sodium | Montelukast Sodium | 67 | 26 |
| Mirtazapine | Mirtazapine | 65 | 13 |
| Lubiprostone | Lubiprostone | 61 | suppressed |
| Ozempic | Semaglutide | 61 | 19 |
| Metformin Hcl | Metformin Hcl | 58 | 19 |
| Midodrine Hcl | Midodrine Hcl | 57 | 14 |
| Azithromycin | Azithromycin | 56 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 15 |
| Meloxicam | Meloxicam | 56 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 16 |
| Movantik | Naloxegol Oxalate | 55 | suppressed |
| Tradjenta | Linagliptin | 53 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 51 | 12 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 50 | 16 |
| Sertraline Hcl | Sertraline Hcl | 49 | 17 |
| Finasteride | Finasteride | 47 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 13 |
| Prednisone | Prednisone | 46 | 24 |
| Buspirone Hcl | Buspirone Hcl | 45 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 12 |
| Latanoprost | Latanoprost | 39 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 37 | suppressed |
| Bumetanide | Bumetanide | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 24 |
| Clonazepam | Clonazepam | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Cilostazol | Cilostazol | 32 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 12 |
| Valsartan | Valsartan | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Restasis | Cyclosporine | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Simvastatin | Simvastatin | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 15 |
| Glipizide Er | Glipizide | 29 | suppressed |
| Klor-Con 10 | Potassium Chloride | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 18 |
| Diclofenac Sodium Er | Diclofenac Sodium | 26 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | 11 |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 25 | 12 |
| Baclofen | Baclofen | 24 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 24 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 24 | suppressed |
| Invokana | Canagliflozin | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Creon | Lipase/Protease/Amylase | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 12 |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 11 |
| Telmisartan | Telmisartan | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Demeclocycline Hcl | Demeclocycline Hcl | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Dofetilide | Dofetilide | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Savella | Milnacipran Hcl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Procrit | Epoetin Alfa | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $357.16 · 4 records | Abbott Laboratories | Brinsupri, TRICLIP, ZEPBOUND | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error